ArticleAccounts of chemical research2016
Programmable Bio-nanochip Platform: A Point-of-Care Biosensor System with the Capacity To Learn.
Article in Accounts of chemical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 60 citations in OpenAlex.
- Artificial Intelligence in Electrochemical Sensing: A Network Evidence Map of Translational Barriers and Pathways to Point-of-Care Deployment.Biosensors · 2026Review
- Artificial intelligence (AI) and machine learning (ML) in ovarian cancer: transforming detection, treatment, and prevention.Journal of ovarian research · 2026Review
- Special Issue "Synthetic Biology for Biosensing in Health and Environmental Applications".Biosensors · 2023Article
- Advancing Healthcare: Synergizing Biosensors and Machine Learning for Early Cancer Diagnosis.Biosensors · 2023Review
- Simultaneous Quantitative SARS-CoV-2 Antigen and Host Antibody Detection and Pre-Screening Strategy at the Point of Care.Bioengineering (Basel, Switzerland) · 2023Article
- Microsystem Advances through Integration with Artificial Intelligence.Micromachines · 2023Review
- Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19.Trends in analytical chemistry : TRAC · 2022Review
- Smart Diagnostics: Combining Artificial Intelligence and In Vitro Diagnostics.Sensors (Basel, Switzerland) · 2022Article
- Article
- The future of early cancer detection.Nature medicine · 2022Review
- Emerging applications of nanotechnology in context to immunology: A comprehensive review.Frontiers in bioengineering and biotechnology · 2022Review
- Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases.Biosensors & bioelectronics · 2021Review
- Review
- Article
- A digital protein microarray for COVID-19 cytokine storm monitoring.Lab on a chip · 2021Article
- Different Approaches to Develop Nanosensors for Diagnosis of Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Application of leukocyte esterase strip test in the screening of periprosthetic joint infections and prospects of high-precision strips.Arthroplasty (London, England) · 2020Review
- Managing COVID-19 With a Clinical Decision Support Tool in a Community Health Network: Algorithm Development and Validation.Journal of medical Internet research · 2020Article
- Clinical decision support tool and rapid point-of-care platform for determining disease severity in patients with COVID-19.Lab on a chip · 2020Article
- Clinical Decision Support Tool and Rapid Point-of-Care Platform for Determining Disease Severity in Patients with COVID-19.medRxiv : the preprint server for health sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The combination of point-of-care (POC) medical microdevices and machine learning has the potential transform the practice of medicine. In this area, scalable lab-on-a-chip (LOC) devices have many advantages over standard laboratory methods, including faster analysis, reduced cost, lower power consumption, and higher levels of integration and automation. Despite significant advances in LOC technologies over the years, several remaining obstacles are preventing clinical implementation and market penetration of these novel medical microdevices. Similarly, while machine learning has seen explosive growth in recent years and promises to shift the practice of medicine toward data-intensive and evidence-based decision making, its uptake has been hindered due to the lack of integration between clinical measurements and disease determinations. In this Account, we describe recent developments in the programmable bio-nanochip (p-BNC) system, a biosensor platform with the capacity for learning. The p-BNC is a "platform to digitize biology" in which small quantities of patient sample generate immunofluorescent signal on agarose bead sensors that is optically extracted and converted to antigen concentrations. The platform comprises disposable microfluidic cartridges, a portable analyzer, automated data analysis software, and intuitive mobile health interfaces. The single-use cartridges are fully integrated, self-contained microfluidic devices containing aqueous buffers conveniently embedded for POC use. A novel fluid delivery method was developed to provide accurate and repeatable flow rates via actuation of the cartridge's blister packs. A portable analyzer instrument was designed to integrate fluid delivery, optical detection, image analysis, and user interface, representing a universal system for acquiring, processing, and managing clinical data while overcoming many of the challenges facing the widespread clinical adoption of LOC technologies. We demonstrate the p-BNC's flexibility through the completion of multiplex assays within the single-use disposable cartridges for three clinical applications: prostate cancer, ovarian cancer, and acute myocardial infarction. Toward the goal of creating "sensors that learn", we have developed and describe here the Cardiac ScoreCard, a clinical decision support system for a spectrum of cardiovascular disease. The Cardiac ScoreCard approach comprises a comprehensive biomarker panel and risk factor information in a predictive model capable of assessing early risk and late-stage disease progression for heart attack and heart failure patients. These marker-driven tests have the potential to radically reduce costs, decrease wait times, and introduce new options for patients needing regular health monitoring. Further, these efforts demonstrate the clinical utility of fusing data from information-rich biomarkers and the Internet of Things (IoT) using predictive analytics to generate single-index assessments for wellness/illness status. By promoting disease prevention and personalized wellness management, tools of this nature have the potential to improve health care exponentially.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.